Moreover, deletion of the CD38 gene prevents fratricide induced by daratumumab (anti-CD38) binding to CD38 on NK cell membranes, leading to a 50% enhancement in anti-tumor activity during combination therapy in multiple myeloma xenograft models (n = 12) [30]. This evidence concerns the gene CD38 and plasma cell myeloma.